In previous studies, GST-II was shown to promote chemotherapy resistance by influencing the biotransformation and metabolic processes (Liang 2010), and Ding’s research confirmed that down-regulation of H19 can block the MAPK/ERK signaling pathway, reducing the levels of MDR1 and GST-II; this was shown to facilitate cell apoptosis and suppress cell viability, eventually reversing the chemotherapy resistance of CD133 + HCC stem cells (Ding et al. 2018). This evidence concerns the gene H19 and hepatocellular carcinoma.